Floxuridine pharma-grade API is supplied as a 2′-deoxy-5-fluorouridine solid with a molecular weight of 246.19 g/mol. The approved commercial dosage form is a sterile lyophilized powder for intravenous or intra-arterial injection after reconstitution; the molecule is a fluorinated pyrimidine antimetabolite that is converted to fluorouracil in target tissues. Published industrial-scale processing data for oral floxuridine tablet, capsule, and granule dosage forms are limited; no oral solid-dose manufacturing scenarios are included. The downstream applications below concentrate on sterile injectable oncology manufacturing, hospital cytotoxic compounding, elastomeric ambulatory infusion, implantable hepatic artery pump refill, and masked clinical trial infusate preparation.

Lyophilized Injectable Product Manufacture Without Terminal Sterilization

Commercial manufacture of floxuridine injection is performed as an aseptic lyophilized solid rather than as a terminal-sterilized aqueous solution. The bulk solution is prepared from pharma-grade API in a water-for-injection vehicle; the single-dose composition contains 500 mg floxuridine per vial, and the point-of-use reconstitution ratio is 5 mL Sterile Water for Injection to produce 100 mg/mL. Batch release is controlled under the USP–NF Floxuridine Injection monograph and the general chapters USP <1> for injectable products, USP <71> for sterility, USP <85> for bacterial endotoxins, USP <788> for subvisible particulate matter, and USP <790> for visible particulates. Drug substance testing includes assay by HPLC, chromatographic purity, residual solvents per USP <467>, and elemental impurities per ICH Q3D. Aseptic processing is conducted in an ISO 7 background cleanroom with an ISO 5 unidirectional airflow critical zone. Depyrogenated Type I borosilicate glass vials and elastomeric closures compliant with USP <381> are used. Vials are washed and depyrogenated in a dry-heat tunnel with a sterilizing zone temperature of 250 °C for a validated residence time. The sterile-filtered solution is passed through a 0.22 µm sterilizing-grade membrane, filled to target volume with a rotary piston or peristaltic pump, and partially stoppered before loading into a freeze dryer. Fill-weight verification is carried out gravimetrically on a calibrated balance with in-process fill volume limits of ±1 % of target. Lyophilization cycle development relies on freeze-drying microscopy and thermal characterization to identify the collapse temperature of the specific formulation; primary drying is conducted at sub-zero product temperature under vacuum, with chamber pressure typically held between 10 Pa and 20 Pa during development. Container closure integrity is confirmed by validated methods such as dye ingress or vacuum decay per USP <1207>. Terminal steam sterilization is not used because aqueous floxuridine is susceptible to hydrolytic degradation and pH shift under elevated heat loads. The finished product type is a single-dose lyophilized cytotoxic vial for intravenous or intra-arterial use; it is stored at controlled room temperature, protected from light, and reconstituted immediately before administration. Published data for the approved product freeze-drying recipe are limited; production parameters are supplier-specific and locked after thermal mapping and media fill validation.

A hospital central intravenous admixture service handles floxuridine under a cytotoxic hazardous-drug program that separates negative-pressure ISO 5 compounding areas from general preparation zones. USP <797> governs sterile preparation, USP <800> sets hazardous drug handling requirements, and the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings classifies floxuridine as an antineoplastic hazardous agent. The lyophilized 500 mg vial is reconstituted with 5 mL Sterile Water for Injection to form a 100 mg/mL stock. For a published hepatic artery infusion protocol starting dose of 0.3 mg/kg/day for 14 days in a 70 kg patient, the total dose is 294 mg; if the infusate is loaded into a 100 mL reservoir, the final concentration is 2.94 mg/mL. Final dilution is performed with 0.9% sodium chloride injection or 5% dextrose injection, and the resulting solution is drawn through a closed-system transfer device to minimize surface contamination. The compounding process uses sporicidal disinfection of vial stoppers and elastomeric port surfaces. A 14-day beyond-use date is assigned only if supported by site-specific stability data, and the product is visually inspected against a black-and-white background for particulate formation and container closure defects. The terminal finished product type is a patient-specific infusion bag, infusion syringe, or implantable pump reservoir under pharmacy-generated labeling.

What Limits Elastomeric Infusor Rate Consistency Across a 14-Day Floxuridine Admixture?

Elastomeric ambulatory infusors are filled with floxuridine admixture when continuous intra-arterial delivery is moved out of the inpatient unit. The device is governed by ISO 28620:2020; the compounding environment remains subject to USP <797> and USP <800>. The reservoir fill is calculated from the dose-volume relationship: a 294 mg total dose diluted in a 100 mL device produces 2.94 mg/mL. Elastomeric pump flow rate is not solely determined by the restrictor diameter; it is influenced by reservoir polymer stiffness, drug solution viscosity, storage temperature, backpressure from the hepatic artery catheter, and fill volume. Manufacturer technical bulletins list labeled flow rates at 25 °C with an acceptance tolerance commonly expressed as ±15 % of nominal rate. Filling is performed under ISO 5 conditions using negative-pressure syringe transfer or a filling adapter, followed by tube priming, clamp closure, and leak testing by visual inspection. The finished product is an ambulatory continuous infusor with a reservoir volume typically 60 mL, 100 mL, or 150 mL. Because elastomeric contraction force decreases at refrigerated temperatures, a device that is stored at 2–8 °C may show delayed flow onset or reduced early flow rate until the reservoir reaches ambient temperature; site-specific temperature studies are required before assigning a beyond-use date for a refrigerated floxuridine infusor.

For implantable hepatic artery infusion pumps, refill operations impose higher particulate and sterility constraints than intravenous admixture because the infusate resides in the pump reservoir at 37 °C for up to 14 days. The procedure is performed under USP <797> and USP <800>; pump manufacturer instructions define allowable non-coring needle gauge, septum puncture count, and residual volume removal. A 500 mg vial is reconstituted to 100 mg/mL, then diluted to reservoir-specific concentration. A 294 mg total dose loaded into a 20 mL implantable pump reservoir yields 14.7 mg/mL; if a 40 mL reservoir is used, the concentration is 7.35 mg/mL. The final concentration is limited by available reservoir volume and the programmed per-day flow rate. The refill process uses a template to locate the pump septum, aspirates the residual volume before fill, and injects the new infusate through a needle-based system. After filling, the delivered volume is documented by the difference between the volume injected and the residual withdrawn; the pump is interrogated to confirm programming parameters. The terminal product is a filled implantable hepatic artery infusion pump reservoir. Repeated septum puncture beyond the manufacturer-specified count can create silicone-core fragments and leakage; therefore the pump body and septum are inspected before each refill and the puncture count is recorded in the device log.

When Randomized Oncology Protocols Require Masked Infusate Sets

Investigator-initiated randomized trials that compare hepatic artery infusion with systemic therapy may require masked infusate preparation for floxuridine and control arms. Compounding is governed by ICH E6(R2), the applicable regulatory IND under 21 CFR 312, and sterile compounding standards USP <797>. An unblinded pharmacist prepares the active infusate by diluting 100 mg/mL floxuridine stock to the protocol-defined concentration; an active-arm calculation of 2.94 mg/mL in a 100 mL reservoir may be used. The control arm uses identical final volume and container type, and both arms are overwrapped with opaque tubing and reservoir covers before release. The final product type is a randomized clinical trial infusate kit labeled with subject identification and kit number only; the preparer maintains the randomization code. The production process includes separate preparation zones, independent double-check by a second unblinded pharmacist, visual particle inspection, and documented chain of custody. Published data for floxuridine-specific masked infusate stability in this configuration are limited; institutional trial pharmacies generally assign a conservative beyond-use date supported by compounding stability data.